Key facts
- This page summarizes Jonathan Violin's Form 4 filing for Viridian Therapeutics, Inc.\DE (VRDN).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 03 Mar 2022, 15:48.
Jonathan Violin - 01 Mar 2022 Form 4 Insider Report for Viridian Therapeutics, Inc.\DE (VRDN)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- VRDN
- Reported as of
- 01 Mar 2022
- Net transaction value
- -$529,491
- SEC form
- 4
- Accepted by SEC
- 03 Mar 2022, 15:48:31 UTC
- Prior SEC filing
- 03 Feb 2022
- Next SEC filing
- 05 Apr 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Lara Meisner, Attorney-in-Fact for Jonathan Violin
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jonathan Violin filed Form 4 for Viridian Therapeutics, Inc.\DE (VRDN) on 03 Mar 2022.
Change
- Previous filing in this sequence was filed on 03 Feb 2022.
- Current net transaction value: -$529,491.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
VRDN
transaction
Common Stock
Sale
- Transaction value
- $336,691
- Shares
- -18,894
- Change %
- -3.1%
- Price
- $17.82
- Shares after
- 582,011
- Date
- 01 Mar 2022
- Ownership
- Direct
- Footnotes
- F1
VRDN
transaction
Common Stock
Sale
- Transaction value
- $192,800
- Shares
- -11,106
- Change %
- -1.9%
- Price
- $17.36
- Shares after
- 570,905
- Date
- 02 Mar 2022
- Ownership
- Direct
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $17.62 to $18.30. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
Footnote F2
This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $17.05 to $18.06. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.